Wuhan LL Science & Technology divulges new MASP2 inhibitors for renal disorders

Aug. 25, 2023

Wuhan LL Science & Technology Development Co. Ltd. has synthesized mannan-binding lectin serine protease 2 (MASP2) inhibitors reported to be useful for the treatment of lupus nephritis and IgA nephropathy, among others.

BioWorld Science Nephrology Patents

Today's news in brief

BioWorld

BioWorld briefs for Aug. 7, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 7, 2025.

Chimerix buyout a win for Jazz with FDA nod for rare glioma drug

BioWorld

Jazz Pharmaceuticals plc is prepped and ready for launch following U.S. FDA accelerated approval of dordaviprone as the first systemic therapy for H3 K27M-mutant...

FDA defends use of PFAS in medical devices

BioWorld MedTech

The U.S. FDA has staked out a position on the use of per- and polyfluoroalkyl substances in medical devices, declaring that the evidence offers no reason to...

Illustration of Microglia cells (red) in Alzheimer´s disease

Two cancer drugs combined modify Alzheimer’s disease in mice

BioWorld

Current treatments for Alzheimer’s disease have limited effects. While they can slow cognitive decline or alleviate symptoms, they do not reverse this complex...